Biology of arteriovenous fistula failure

Journal of Nephrology

Volumn 20, Issue 2, 2007, Pages 150-163

  Roy Chaudhury, Prabir ^a   Spergel, Lawrence M ^b   Besarab, Anatole ^c   Asif, Arif ^d   Ravani, Pietro ^e,f  

^a UNIVERSITY OF CINCINNATI   (United States)

^b Dialysis Management Medical Group   (United States)

^c HENRY FORD HEALTH SYSTEM   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^f Division of Nephrology and Dialysis   (Italy)

Author keywords

Arteriovenous fistula; Primary failure; Risk factors; Vascular access outcomes

Indexed keywords

CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ELASTASE; FISH OIL; NITRIC OXIDE; RAPAMYCIN; ROSIGLITAZONE; SUPEROXIDE;

AGE DISTRIBUTION; ARTERIOVENOUS MALFORMATION; ARTERIOVENOUS SHUNT; ARTERIOVENOUS SHUNT FAILURE; ARTERY INTIMA PROLIFERATION; BLOOD FLOWMETRY; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL DIAMETER; CELL THERAPY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOPPLER FLOWMETER; GENE THERAPY; GRAFT DYSFUNCTION; HEMODIALYSIS; HUMAN; NONHUMAN; PATHOGENESIS; PATHOLOGY; PERIPHERAL VASCULAR DISEASE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SHEAR STRESS; STENOSIS; THROMBOSIS; VASCULAR ACCESS; VASODILATATION;

ANIMALS; ARTERIOVENOUS SHUNT, SURGICAL; CLINICAL TRIALS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; TREATMENT FAILURE;

EID: 34447517762     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Roy-Chaudhury P, Kelly BS, Zhang J, Narayana A, Desai P, Melham M, Duncan H, Heffelfinger SC. Hemodialysis vascular access dysfunction: from pathophysiology to novel therapies. Blood Purif 2003; 21: 99-110.
2. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity, J Am Soc Nephrol 1996; 7: 523-35.
3. McCarley P, Wingard RL, Shyr Y, Pettus W, Hakim RM, Ikizler TA. Vascular access blood flow monitoring reduces access morbidity and costs. Kidney Int 2001; 60: 1164-72.
4. Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol 2006; 17: 1112-27.
5. Roy-Chaudhury P, Kelly BS, Melhem M, Zhang J, Li J, Desai P, Munda R, Heffelfinger SC. Vascular access in hemodialysis: issues, management, and emerging concepts. Cardiol Clin 2005; 23: 249-73.
6. Patel ST, Hughes J, Mills JL Sr. Failure of arteriovenous fistula maturation: an unintended consequence of exceeding dialysis outcome quality initiative guidelines for hemodialysis access. J Vasc Surg 2003; 38: 439-45 [discussion: 45].
7. Tordoir JH, Rooyens P, Dammers R, van der Sande FM, de Haan M, Yo TI. Prospective evaluation of failure modes in autogenous radiocephalic wrist access for haemodialysis. Nephrol Dial Transplant 2003; 18: 378-83.
8. Allon M, Robbin ML. Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. Kidney Int 2002; 62: 1109-24.
9. Dixon BS, Novak L, Fangman J. Hemodialysis vascular access survival: upper-arm native arteriovenous fistula. Am J Kidney Dis 2002; 39: 92-101.
10. Oliver MJ, McCann RL, Indridason OS, Butterly DW, Schwab SJ. Comparison of transposed brachiobasilic fistulas to upper arm grafts and brachiocephalic fistulas. Kidney Int 2001; 60: 1532-9.
11. Rooijens PP, Burgmans JP, Yo TI, Hop WC, de Smet AA, van den Dorpel MA, Fritschy WM, de Groot HG, Burger H, Tordoir JH. Autogenous radial-cephalic or prosthetic brachial-antecubital forearm loop AVF in patients with compromised vessels? A randomized, multicenter study of the patency of primary hemodialysis access. J Vasc Surg 2005; 42: 481-6 [discussion: 7].
12. Beathard GA, Arnold P, Jackson J, Litchfield T. Aggressive treatment of early fistula failure. Kidney Int 2003; 64: 1487-94.
13. National Kidney Foundation. DOQI clinical practice guidelines for vascular access. Am J Kidney Dis 2006; 48: S177-247.
14. Falk A. Maintenance and salvage of arteriovenous fistulas. J Vasc Interv Radiol 2006; 17: 807-13.
15. Nasser GN, Rhee E, Achkar K. Endovascular treatment of the "failing to mature" arteriovenous fistula. Clin J Am Soc Nephrol 2006; 1: 275-80.
16. Roy-Chaudhury P, Zhang J, Krishnamoorthy M, Wang Y, Banerjee R, Tevar A, Heffelfinger S, Munda R. Cellular phenotypes in dialysis access stenosis: myofibroblasts, fibroblasts and contractile smooth muscle cells. J Am Soc Nephrol 2006; 17: 75A.
17. Stracke S, Konner K, Kostlin I, Friedl R, Jehle PM, Hombach V, Keller F, Waltenberger J. Increased expression of TGF-beta1 and IGF-I in inflammatory stenotic lesions of hemodialysis fistulas. Kidney Int 2002; 61: 1011-9.
18. Weiss MF, Scivittaro V, Anderson JM. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis 2001; 37: 970-80.
19. Roy-Chaudhury P, Samaha A, Zhang J, Krishnamoorthy M, Wang Y, Banerjee R, Munda R, Heffelfinger S. Aggressive early neointimal hyperplasia contributes to AV fistula maturation failure. J Am Soc Nephrol 2006; 17: F-PO1056.
20. Zarins CK, Giddens DP, Bharadvaj BK, Sottiurai VS, Mabon RF, Glagov S. Carotid bifurcation atherosclerosis: quantitative correlation of plaque localization with flow velocity profiles and wall shear stress. Circ Res 1983; 53: 502-14.
21. Glagov S, Zarins C, Giddens DP, Ku DN. Hemodynamics and atherosclerosis: insights and perspectives gained from studies of human arteries. Arch Pathol Lab Med 1988; 112: 1018-31.
22. Mattsson EJ, Kohler TR, Vergel SM, Clowes AW. Increased blood flow induces regression of intimal hyperplasia. Arterioscler Thromb Vasc Biol 1997; 17: 2245-9.
23. Guzman RJ, Abe K, Zarins CK. Flow-induced arterial enlargement is inhibited by suppression of nitric oxide synthase activity in vivo. Surgery 1997; 122: 273-9 [discussion: 279-80].
24. Paszkowiak JJ, Dardik A. Arterial wall shear stress: observations from the bench to the bedside. Vasc Endovascular Surg 2003; 37: 47-57.
25. Keren G. Compensatory enlargement, remodeling, and restenosis. Adv Exp Med Biol 1997; 430: 187-96.
26. Meyerson SL, Skelly CL, Curi MA, Shakur UM, Vosicky JE, Glagov S, Schwartz LB, Christen T, Gabbiani G. The effects of extremely low shear stress on cellular proliferation and neointimal thickening in the failing bypass graft. J Vasc Surg 2001; 34: 90-7.
27. Honda HM, Hsiai T, Wortham CM, Chen M, Lin H, Navab M, Demer LL. A complex flow pattern of low shear stress and flow reversal promotes monocyte binding to endothelial cells. Atherosclerosis 2001; 158: 385-90.
28. Dardik A, Chen L, Frattini J, Asada H, Aziz F, Kudo FA, Sumpio BE. Differential effects of orbital and laminar shear stress on endothelial cells. J Vasc Surg 2005; 41: 869-80.
29. Gambillara V, Montorzi G, Haziza-Pigeon C, Stergiopulos N, Silacci P. Arterial wall response to ex vivo exposure to oscillatory shear stress. J Vasc Res 2005; 42: 535-44.
30. Hayashi K, Mori K, Miyazaki H. Biomechanical response of femoral vein to chronic elevation of blood pressure in rabbits. Am J Physiol Heart Circ Physiol 2003; 284: H511-8.
31. Lehoux S, Castier Y, Tedgui A. Molecular mechanisms of the vascular responses to haemodynamic forces. J Intern Med 2006; 259: 381-92.
32. Lehoux S, Lemarie CA, Esposito B, Lijnen HR, Tedgui A. Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. Circulation 2004; 109: 1041-7.
33. Tronc F, Wassef M, Esposito B, Henrion D, Glagov S, Tedgui A. Role of NO in flow-induced remodeling of the rabbit common carotid artery. Arterioscler Thromb Vasc Biol 1996; 16: 1256-62.
34. Lehoux S, Tedgui A. Cellular mechanics and gene expression in blood vessels. J Biomech 2003; 36: 631-43.
35. Castier Y, Brandes RP, Leseche G, Tedgui A, Lehoux S. p47phox-dependent NADPH oxidase regulates flow-induced vascular remodeling. Circ Res 2005; 97: 533-40.
36. Castier Y, Lehoux S, Hu Y, Fonteinos G, Tedgui A, Xu Q. Characterization of neointima lesions associated with arteriovenous fistulas in a mouse model. Kidney Int 2006; 70: 315-20.
37. Corpataux JM, Haesler E, Silacci P, Ris HB, Hayoz D. Low-pressure environment and remodelling of the forearm vein in Brescia-Cimino haemodialysis access. Nephrol Dial Transplant 2002; 17: 1057-62.
38. Miller PE, Tolwani A, Luscy CP, Deierhoi MH, Bailey R, Redden DT, Allon M. Predictors of adequacy of arteriovenous fistulas in hemodialysis patients. Kidney Int 1999; 56: 275-80.
39. Lok CE, Allon M, Moist L, Oliver MJ, Shah H, Zimmerman D. Risk equation determining unsuccessful cannulation events and failure to maturation in arteriovenous fistulas (REDUCE FTM I). J Am Soc Nephrol 2006; 17: 3204-12.
40. He C, Charoenkul V, Kahn T, Langhoff E, Uribarri J, Sedlacek M. Impact of the surgeon on the prevalence of arteriovenous fistulas. ASAIO J 2002; 48: 39-40.
41. Ernandez T, Saudan P, Berney T, Merminod T, Bednarkiewicz M, Martin PY. Risk factors for early failure of native arteriovenous fistulas. Nephron Clin Pract 2005; 101: c39-44.
42. Konner K. The initial creation of native arteriovenous fistulas: surgical aspects and their impact on the practice of nephrology. Semin Dial 2003; 16: 291-8.
43. van der Linden J, Lameris TW, van den Meiracker AH, de Smet AA, Blankestijn PJ, van den Dorpel MA. Forearm venous distensibility predicts successful arteriovenous fistula. Am J Kidney Dis 2006; 47: 1013-9.
44. Dixon BS. Why don't fistulas mature? Kidney Int 2006; 70: 1413-22.
45. Krishnamoorthy M, Wang Y, Zhang J, Sinha Roy A, Khoury S, Desai P, Banerjee R, Roy-Chaudhury P. Altering hemodynamics through computer modeling of AV fistula configuration: opportunities for reducing AV fistula failure. J Am Soc Nephrol 2006; 17: 74A.
46. Longest PW, Kleinstreuer C, Andreotti PJ. Computational analyses and design improvements of graft-to-vein anastomoses. Crit Rev Biomed Eng 2000; 28: 141-7.
47. Longest PW, Kleinstreuer C. Computational haemodynamics analysis and comparison study of arterio-venous grafts. J Med Eng Technol 2000; 24: 102-10.
48. Konner K. The anastomosis of the arteriovenous fistula: common errors and their avoidance. Nephrol Dial Transplant 2002; 17: 376-9.
49. Konner K, Nonnast-Daniel B, Ritz E. The arteriovenous fistula. J Am Soc Nephrol 2003; 14: 1669-80.
50. Lee T, Barker J, Allon M. Needle infiltration of arteriovenous fistulae in hemodialysis: risk factors and consequences. Am J Kidney Dis 2006; 47: 1020-6.
51. Unnikrishnan S, Huynh TN, Brott BC, Ito Y, Cheng CH, Shih AM, Allon M, Anayiotos AS. Turbulent flow evaluation of the venous needle during hemodialysis. J Biomech Eng 2005; 127: 1141-6.
52. Chang CJ, Ko PJ, Hsu LA, Ko YS, Ko YL, Chen CF, Huang CC, Hsu TS, Lee YS, Pang JH. Highly increased cell proliferation activity in the restenotic hemodialysis vascular access after percutaneous transluminal angioplasty: implication in prevention of restenosis. Am J Kidney Dis 2004; 43: 74-84.
53. Chang CJ, Ko YS, Ko PJ, Hsu LA, Chen CF, Yang CW, Hsu TS, Pang JH. Thrombosed arteriovenous fistula for hemodialysis access is characterized by a marked inflammatory activity. Kidney Int 2005; 68: 1312-9.
54. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-80.
55. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-31.
56. Shi Y, O'Brien JE, Fard A, Mannion JD, Wang D, Zalewski A. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 1996; 94: 1655-64.
57. Shi Y, O'Brien JE Jr, Mannion JD, Morrison RC, Chung W, Fard A, Zalewski A. Remodeling of autologous saphenous vein grafts: the role of perivascular myofibroblasts. Circulation 1997; 95: 2684-93.
58. Scott NA, Cipolla GD, Ross CE, Dunn B, Martin FH, Simonet L, Wilcox JN. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation 1996; 93: 2178-87.
59. Misra S, Doherty MG, Woodrum D, Homburger J, Mandrekar JN, Elkouri S, Sabater EA, Bjarnason H, Fu AA, Glockner JF, Greene EL, Mukhopadhyay D. Adventitial remodeling with increased matrix metalloproteinase-2 activity in a porcine arteriovenous polytetrafluoroethylene grafts. Kidney Int 2005; 68: 2890-900.
60. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, Nagai R. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8: 403-9.
61. Diao Y GM, Guthrie S, Scott E, Segal MS. Role of circulating progenitor cells in the development of venous intimal hyperplasia. J Am Soc Nephrol 2002; 13: 58A-9A.
62. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004; 95: 343-53.
63. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
64. Szmitko PE, Fedak PW, Weisel RD, Stewart DJ, Kutryk MJ, Verma S. Endothelial progenitor cells: new hope for a broken heart. Circulation 2003; 107: 3093-100.
65. Urao N. Endothelial progenitor cells and vascular repair. Abstract presented at the 2005 AHA Meeting.
66. Werner N, Junk S, Laufs U, Link A, Walenta K, Bohm M, Nickenig G. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 2003; 93: e17-24.
67. Griese DP, Ehsan A, Melo LG, Kong D, Zhang L, Mann MJ, Pratt RE, Mulligan RC, Dzau VJ. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation 2003; 108: 2710-5.
68. Shears LL 2nd, Kibbe MR, Murdock AD, Billiar TR, Lizonova A, Kovesdi I, Watkins SC, Tzeng E. Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg 1998; 187: 295-306.
69. Kipshidze N, Dangas G, Tsapenko M, Moses J, Leon MB, Kutryk M, Serruys P. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol 2004; 44: 733-9.
70. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-7.
71. Kong D, Melo LG, Gnecchi M, Zhang L, Mostoslavsky G, Liew CC, Pratt RE, Dzau VJ. Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries. Circulation 2004; 110: 2039-46.
72. Joannides R, Bakkali EH, Le Roy F, Rivault O, Godin M, Moore N, Fillastre JP, Thuillez C. Altered flow-dependent vasodilatation of conduit arteries in maintenance haemodialysis. Nephrol Dial Transplant 1997; 12: 2623-8.
73. Himmelfarb J, Stenvinkel P, Alp Ikizler T, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-38.
74. Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, Blumberg JB. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001; 59: 1960-6.
75. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
76. Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 2005; 46: 186-202.
77. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, Boger R. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in endstage renal disease. J Am Soc Nephrol 2002; 13: 490-6.
78. Choi JH, Kim KL, Huh W, Kim B, Byun J, Suh W, Sung J, Jeon ES, Oh HY, Kim DK. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 2004; 24: 1246-52.
79. Eizawa T, Murakami Y, Matsui K, Takahashi M, Muroi K, Amemiya M, Takano R, Kusano E, Shimada K, Ikeda U. Circulating endothelial progenitor cells are reduced in hemodialysis patients. Curr Med Res Opin 2003; 19: 627-33.
80. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107: 992-5.
81. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-8.
82. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, Dagenais GR. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005; 293: 1338-47.
83. Safar ME, London GM, Plante GE. Arterial stiffness and kidney function. Hypertension 2004; 43: 163-8.
84. Mourad JJ, Girerd X, Boutouyrie P, Laurent S, Safar M, London G. Increased stiffness of radial artery wall material in end-stage renal disease. Hypertension 1997; 30: 1425-30.
85. Covic A, Gusbeth-Tatomir P, Goldsmith DJ. Arterial stiffness in renal patients: an update. Am J Kidney Dis 2005; 45: 965-77.
86. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 2004; 95: 560-7.
87. Chen NX, Moe SM. Uremic vascular calcification. J Investig Med 2006; 54: 380-4.
88. Kim YO, Choi YJ, Kim JI, Kim YS, Kim BS, Park CW, Song HC, Yoon SA, Chang YS, Bang BK. The impact of intimamedia thickness of radial artery on early failure of radiocephalic arteriovenous fistula in hemodialysis patients. J Korean Med Sci 2006; 21: 284-9.
89. Wali MA, Eid RA, Dewan M, Al-Homrany MA. Intimal changes in the cephalic vein of renal failure patients before arterio-venous fistula (AVF) construction. J Smooth Muscle Res 2003; 39: 95-105.
90. Fukasawa M, Matsushita K, Kamiyama M, Mikami Y, Araki I, Yamagata Z, Takeda M. The methylentetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis 2003; 41: 637-42.
91. Heine GH, Ulrich C, Sester U, Sester M, Kohler H, Girndt M. Transforming growth factor beta1 genotype polymorphisms determine AV fistula patency in hemodialysis patients. Kidney Int 2003; 64: 1101-7.
92. Lin CC, Yang WC, Lin SJ, Chen TW, Lee WS, Chang CF, Lee PC, Lee SD, Su TS, Fann CS, Chung MY. Length polymorphism in heme oxygenase-1 is associated with arteriovenous fistula patency in hemodialysis patients. Kidney Int 2006; 69: 165-72.
93. Diskin CJ, Stokes TJ Jr, Pennell AT. Pharmacologic intervention to prevent hemodialysis vascular access thrombosis. Nephron 1993; 64: 1-26.
94. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney Int 1994; 45: 1477-83.
95. Schmitz PG, McCloud LK, Reikes ST, Leonard CL, Gellens ME. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. J Am Soc Nephrol 2002; 13: 184-90.
96. Gradzki R, Dhingra RK, Port FK, Roys E, Weitzel WF, Messana JM. Use of ACE inhibitors is associated with prolonged survival of arteriovenous grafts. Am J Kidney Dis 2001; 38: 1240-4.
97. Dember LM, Kaufman JS, Beck GJ, Dixon BS, Gassman JJ, Greene T, Himmelfarb J, Hunsicker LG, Kusek JW, Lawson JH, Middleton JP, Radeva M, Schwab SJ, Whiting JF, Feldman HI. Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial. Clin Trials 2005; 2: 413-22.
98. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V, Marks A, Badimon JJ. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999; 99: 2164-70.
99. Murthy SN, Obregon DF, Chattergoon NN, Fonseca NA, Mondal D, Dunne JB, Diez JG, Jeter JR, Kadowitz PJ, Agrawal KC, McNamara DB, Fonseca VA. Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation, and intimal hyperplasia in Sprague-Dawley rats fed a high methionine diet. Metabolism 2005; 54: 645-52.
100. Wang CH, Ciliberti N, Li SH, Szmitko PE, Weisel RD, Fedak PW, Al-Omran M, Cherng W J, Li RK, Stanford WL, Verma S. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation 2004; 109: 1392-400.
101. Fukuda D, Sata M, Tanaka K, Nagai R. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation 2005; 111: 926-31.
102. Hausleiter J, Kastrati A, Mehilli J, Vogeser M, Zohlnhofer D, Schuhlen H, Goos C, Pache J, Dotzer F, Pogatsa-Murray G, Dirschinger J, Heemann U, Schomig A. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 2004; 110: 790-5.
103. Takagi T, Yamamuro A, Tamita K, Katayama M, Morioka S. Thiazolidinedione treatment attenuates diffuse neointimal hyperplasia in restenotic lesions after coronary stent implantation in type 2 diabetic patients: an intravascular ultrasound study. J Cardiol 2005; 45: 139-47.
104. Nugent HM, Groothuis A, Seifert P, Guerraro JL, Nedelman M, Mohanakumar T, Edelman ER. Perivascular endothelial implants inhibit intimal hyperplasia in a model of arteriovenous fistulae: a safety and efficacy study in the pig. J Vasc Res 2002; 39: 524-33.
105. Nugent HM, Rogers C, Edelman ER. Endothelial implants inhibit intimal hyperplasia after porcine angioplasty. Circ Res 1999; 84: 384-91.
106. Kelly B, Melhem M, Zhang J, Kasting G, Li J, Krishnamoorthy M, Heffelfinger S, Rudich S, Desai P, Roy-Chaudhury P. Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model. Nephrol Dial Transplant 2006; 21: 2425-31.
107. Sukhatme V. Vascular access stenosis: prospects for prevention and therapy. Kidney Int 1996; 49: 1161-74.
108. Qian HS, Channon K, Neplioueva V, Wang Q, Finer M, Tsui L, George SE, McArthur J. Improved adenoviral vector for vascular gene therapy: beneficial effects on vascular function and inflammation. Circ Res 2001; 88: 911-7.
109. Corgentech and Bristol-Myers Squibb announce results from edifoligide (E2F Decoy) phase 3 trial for coronary artery bypass graft failure (2005) [monograph on the Internet] [cited 2005 Jun 8]. Available from: http://news-room.bms.com/index.php?s=press_releases&item=65.
110. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, Namini H, Hamdan AD, Roddy SP, Belkin M, Berceli SA, DeMasi RJ, Samson RH, Berman SS. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 2006; 43:742-51 [discussion: 51].
111. Trinam® (EG004) - treatment to prevent blocking of blood vessels after surgery. Ark Therapeutics (2006) [monograph on the Internet] [cited 2007 Mar 7]. Available from: http://www.arktherapeutics.com/main/ products.php?content=products_trinam.
112. Fuster V, Charlton P, Boyd A. Clinical protocol: a phase IIb, randomized, multicenter, double-blind study of the efficacy and safety of Trinam (EG004) in stenosis prevention at the graft-vein anastomosis site in dialysis patients. Hum Gene Ther 2001; 12: 2025-7.
113. Ikeno F, Lyons J, Kaneda H, Baluom M, Benet LZ, Rezaee M. Novel percutaneous adventitial drug delivery system for regional vascular treatment. Catheter Cardiovasc Interv 2004; 63: 222-30.